Colgate Palmolive Co (CL)
NYSE · Price as of · Nasdaq Real Time Price
- Analysts20
- Implied upside+0.8%
- Target range$87.00 to $110.00
- EPS expected$0.93 +1.7%
- A year ago$0.91
- Revenue expected$5.33B +4.0%
- Estimate range$0.89 to $0.95
How Congress has done in CL
Every purchase of CL disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.
| Measure | CL | SPY |
|---|---|---|
| Median 12-month return after purchase | +9.9% | +25.4% |
| Median difference vs SPY | -15.4% | — |
| Purchases that beat SPY | 0 of 5 (0%) | — |
| Members who bought | 4 | — |
Most frequent buyers: Lisa McClain (2), John Boozman (1), Julie Johnson (1), Rick Larsen (1).
These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 3 of the 5 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.
Congress trades in CL
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-09-02 | Kevin Hern OK | Sale (Partial) | $1,001 - $15,000 | |
| 2026-09-02 | Kevin Hern OK | Sale | $1,001 - $15,000 | |
| 2026-08-31 | Kevin Hern OK | Sale | $1,001 - $15,000 | |
| 2026-08-31 | Kevin Hern OK | Sale (Full) | $1,001 - $15,000 | |
| 2026-08-27 | Kevin Hern OK | Sale (Partial) | $1,001 - $15,000 |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | October 2, 2026 | View on EDGAR |
| 4 | October 2, 2026 | View on EDGAR |
| 4 | October 2, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
Articles that mention Colgate Palmolive without it being the main subject.
Frequently asked questions
When does CL report earnings?
Colgate Palmolive Co (CL) is scheduled to report quarterly results on October 30, 2026, before the open. The 17-analyst consensus is $0.93 per share on revenue of $5.33B for the quarter ended September 30, 2026, against $0.91 and $5.13B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.
What do analysts expect for CL?
20 analysts cover Colgate Palmolive Co (CL). The consensus rating is Buy. The average price target is $98.15, in a range of $87.00 to $110.00.
Are insiders buying or selling CL?
We have no qualifying Form 4 insider purchases or sales on record for Colgate Palmolive Co (CL). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Has Congress made money trading CL?
4 members of Congress have disclosed buying CL in the last 5 years, 5 purchases in total. Measured over the 12 months after each trade date, the median purchase returned +9.9% against +25.4% for SPY over the same windows, and 0 of the 5 (0%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.
Where can I see CL SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed October 2, 2026.